Circ_CHMP5 aggravates oxidized low-density lipoprotein-induced damage to human umbilical vein endothelial cells through miR-516b-5p/TGFβR2 axis
Related Experiment Video
Updated: Jul 29, 2025

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
Published on: October 4, 2019
Yueru Wang1, Ping Liu2, Xiaoyan Chen3
1Department of Internal Medicine-Cardiovascular, Shanxi Provincial People's Hospital, Taiyuan City, Shanxi, China.
Insights
CircRNA-charged multivesicular body protein 5 (circ_CHMP5) exacerbates atherosclerosis by impairing human umbilical vein endothelial cells. Silencing circ_CHMP5 protects against ox-LDL-induced damage via the miR-516b-5p/TGFβR2 pathway, offering potential therapeutic strategies.
Area of Science:
- Cardiovascular Biology
- Molecular Biology
- Cell Biology
Background:
- Atherosclerosis (AS) is a leading cause of mortality in the elderly.
- Endothelial cell dysfunction in human umbilical vein endothelial cells (HUVECs) is implicated in AS pathogenesis.
- CircRNA-charged multivesicular body protein 5 (circ_CHMP5) has been identified as a potential contributor to AS progression.
Purpose of the Study:
- To investigate the role of circ_CHMP5 in AS.
- To elucidate the underlying molecular mechanisms involving miR-516b-5p and transforming growth factor beta receptor 2 (TGFβR2).
- To evaluate the therapeutic potential of targeting circ_CHMP5 in AS.
Main Methods:
- Quantitative real-time polymerase chain reaction (qRT-PCR) to measure gene and microRNA expression.
- Cell proliferation assays (EdU, CCK-8), apoptosis assays (flow cytometry), and tube formation assays.
- Western blot for protein expression analysis and dual-luciferase reporter/RNA-pull down assays to confirm molecular interactions.
Main Results:
- Circ_CHMP5 levels were elevated in AS patients and ox-LDL-treated HUVECs.
- Ox-LDL impaired HUVEC proliferation and angiogenesis while increasing apoptosis; circ_CHMP5 knockdown reversed these effects.
- Circ_CHMP5 influenced ox-LDL-induced HUVEC dysfunction through the miR-516b-5p/TGFβR2 axis.
Conclusions:
- Circ_CHMP5 knockdown protects against ox-LDL-induced HUVEC injury by modulating the miR-516b-5p and TGFβR2 pathway.
- These findings suggest circ_CHMP5 as a novel therapeutic target for AS treatment.
Background:
Atherosclerosis (AS) was one of the main causes of death in the elderly, and lesions in human umbilical vein endothelial cells (HUVECs) could lead to AS. CircRNA-charged multivesicular body protein 5 (circ_CHMP5) was reported to participate in the progression of AS.
Methods:
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the levels of circ_CHMP5, miR-516b-5p, and transforming growth factor beta receptor 2 (TGFβR2) in AS patients or ox-LDL-induced HUVECs. 5-Ethynyl-2'-deoxyuridine and cell counting kit-8 assays were performed to detect cell proliferation. Proteins expression was assessed by western blot assay. Cell apoptosis was examined by flow cytometry. Tube formation assay was utilized to measure the tube formation ability of HUVCEs. The targeting relationships between miR-516b-5p and circ_CHMP5 or TGFβR2 were confirmed by dual-luciferase reporter assay and RNA-pull down assay.
Results:
Circ_CHMP5 was enhanced in the serum of AS patients and ox-LDL-exposure HUVECs. Ox-LDL blocked proliferation and tube formation of HUVECs and induced cell apoptosis, and circ_CHMP5 knockdown reversed these effects. In addition, circ_CHMP5 regulated the growth of ox-LDL-induced HUVECs through miR-516b-5p and TGFβR2. Moreover, the effects of circ_CHMP5 knockdown on ox-LDL-induced HUVECs were obviously recovered by downregulation of miR-516b-5p, and overexpression of TGFβR2 restored the effects of miR-516b-5p upregulation on ox-LDL-stimulated HUVECs.
Conclusion:
Silence of circ_CHMP5 overturned ox-LDL-treated inhibition of HUVECs proliferation and angiogenesis by miR-516b-5p and TGFβR2. These results provided new solutions for the treatment of AS.
Related Concept Videos
TGF - β Signaling Pathway
Cholesterol: Significance and Regulation
Considering cholesterol and...

